[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

February 2020 - April 2015

Decade

Year

Issue

February 2020, Vol 6, No. 2, Pages 171-308

Original Investigation

Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program

Abstract Full Text
open access
JAMA Oncol. 2020;6(2):196-204. doi:10.1001/jamaoncol.2019.4728

This cluster-randomized clinical trial examines whether providing a geriatric assessment summary and geriatric assessment–guided recommendations to oncologists can improve communication about aging-related concerns.

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials

Abstract Full Text
JAMA Oncol. 2020;6(2):206-216. doi:10.1001/jamaoncol.2019.4097

This meta-analysis of randomized clinical trials assesses overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeted radioisotopes and compares the effects of α-emitting with β-emitting radioisotopes.

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

Abstract Full Text
open access
JAMA Oncol. 2020;6(2):217-225. doi:10.1001/jamaoncol.2019.4636

This secondary analysis of the PREVAIL and AFFIRM randomized clinical trials examines the association between the detection of new unconfirmed lesions detected on follow-up bone scans and outcomes in enzalutamide-treated men with metastatic castration-resistant prostate cancer (mCRPC).

Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era

Abstract Full Text
JAMA Oncol. 2020;6(2):227-235. doi:10.1001/jamaoncol.2019.4648

This cohort study assesses the association between cancer treatment and CD4 count and RNA levels in adults with human immunodeficiency virus.

Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(2):237-246. doi:10.1001/jamaoncol.2019.4889

This comparative effectiveness study assesses whether proton therapy in the setting of concurrent chemoradiotherapy is associated with fewer 90-day unplanned hospitalizations or other adverse events and similar disease-free and overall survival compared with photon chemoradiotherapy among patients with nonmetastatic cancer.

Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries

Abstract Full Text
JAMA Oncol. 2020;6(2):248-254. doi:10.1001/jamaoncol.2019.3994

This cohort study compares idelalisib treatment outcomes in the clinical setting among Medicare beneficiaries with outcomes in clinical trial data.

Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(2):255-263. doi:10.1001/jamaoncol.2019.4477

This randomized clinical trial compares the long-term survival outcomes after repeat hepatectomy with those after percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma.

Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(2):264-270. doi:10.1001/jamaoncol.2019.4668

This cohort study evaluates the association between body composition and the risk of death based on the ratio of planned vs administered dose of chemotherapy in women with breast cancer.

Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain: A Systematic Review and Meta-Analysis

Abstract Full Text
open access
JAMA Oncol. 2020;6(2):271-278. doi:10.1001/jamaoncol.2019.5233

This systematic review and meta-analysis provides an updated synthesis of the published randomized clinical trials into the use and advantages of acupuncture and/or acupressure among patients with cancer pain.

Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis

Abstract Full Text
online only
JAMA Oncol. 2020;6(2):e194107. doi:10.1001/jamaoncol.2019.4107

This pooled analysis from 10 cohort studies that included more than 1.4 million participants evaluates whether an association exists between risk of lung cancer and the habitual consumption of dietary fiber (the main source of prebiotics) or yogurt (a probiotic food).

Brief Report

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2020;6(2):e193332. doi:10.1001/jamaoncol.2019.3332

This prespecified correlative analysis of a randomized clinical trial evaluates the feasibility of implementing the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in the phase 3 COMET-2 trial.

Research Letter

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

Abstract Full Text
JAMA Oncol. 2020;6(2):293-294. doi:10.1001/jamaoncol.2019.5098

This case-control study examines the association of Listeria monocytogenes susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma.

Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(2):294-296. doi:10.1001/jamaoncol.2019.5102

This pooled analysis of data from phase 3 randomized clinical trials assesses the association of sex with toxic effects, treatment adherence, surgical procedures, and long-term outcomes after standard multimodal treatment in patients with rectal cancer.

Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma

Abstract Full Text
JAMA Oncol. 2020;6(2):296-298. doi:10.1001/jamaoncol.2019.5426

This cohort study compares the use of different bone-modifying agents among Medicare beneficiaries with multiple myeloma.

Review

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review

Abstract Full Text
JAMA Oncol. 2020;6(2):281-290. doi:10.1001/jamaoncol.2019.3869

This review describes the development and use of axicabtagene ciloleucel for treatment in patients with refractory large B-cell lymphoma.

JAMA Oncology Clinical Challenge

A Diffuse Medullary Hypercaptation With No Bone Lesion

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(2):291-292. doi:10.1001/jamaoncol.2019.4655

A 71-year-old man presented with a 3-year history of pericarditis and pleural effusions; imaging and biopsy results showed diffuse medullary hypercaptation in the bone marrow and spleen. What is your diagnosis?

Viewpoint

De-escalating Breast Cancer Surgery—Where Is the Tipping Point?

Abstract Full Text
JAMA Oncol. 2020;6(2):183-184. doi:10.1001/jamaoncol.2019.4849

This Viewpoint provides a perspective on recent trials focused on reducing the incidence of surgery in the treatment of breast cancer.

Survival in Oligometastatic Prostate Cancer—A New Dawn or the Will Rogers Phenomenon?

Abstract Full Text
JAMA Oncol. 2020;6(2):185-186. doi:10.1001/jamaoncol.2019.4724

This Viewpoint describes potential improvements in classification of cases of oligometastatic prostate cancer and resulting research opportunities.

Framing New Models to Expand Access to Radiotherapy in Limited Resource Settings—Social Entrepreneurship

Abstract Full Text
JAMA Oncol. 2020;6(2):187-188. doi:10.1001/jamaoncol.2019.5107

This Viewpoint explores the potential for social entrepreneurship among diasporans from low- and middle-income countries to improve access to radiotherapy in their home countries.

Invited Commentary

Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults

Abstract Full Text
JAMA Oncol. 2020;6(2):204-205. doi:10.1001/jamaoncol.2019.4708

Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer

Abstract Full Text
JAMA Oncol. 2020;6(2):225-226. doi:10.1001/jamaoncol.2019.4635

Untangling the Effects of Chemotherapy and HIV on CD4 Counts—Implications for Immunotherapy in HIV and Cancer

Abstract Full Text
JAMA Oncol. 2020;6(2):235-236. doi:10.1001/jamaoncol.2019.4634

Proton-Based Chemoradiotherapy—What Level of Evidence Is Necessary to Justify Its Widespread Use?

Abstract Full Text
JAMA Oncol. 2020;6(2):246-247. doi:10.1001/jamaoncol.2019.4875
JAMA Oncology Patient Page

Ascites, or Fluid in the Belly, in Patients With Cancer

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):308. doi:10.1001/jamaoncol.2019.5409

This Patient Page describes the causes, symptoms, diagnosis, and treatment of ascites in patients with cancer.

Cancer Care Chronicles

The “Art” of Bone Marrow Transplantation

Abstract Full Text
JAMA Oncol. 2020;6(2):189. doi:10.1001/jamaoncol.2019.4738

This essay details some of the limitations of medical science in managing patients undergoing bone marrow transplantation and emphasizes the importance of the arts for the quality of life of these patients.

Poetry and Oncology

Delivering Good News

Abstract Full Text
JAMA Oncol. 2020;6(2):303. doi:10.1001/jamaoncol.2019.5248
Comment & Response

Different Biomarker Modalities and Response to Anti–PD-1/PD-L1 Therapies

Abstract Full Text
JAMA Oncol. 2020;6(2):298-299. doi:10.1001/jamaoncol.2019.5148

Different Biomarker Modalities and Response to Anti–PD-1/PD-L1 Therapies—Reply

Abstract Full Text
JAMA Oncol. 2020;6(2):299. doi:10.1001/jamaoncol.2019.5154

Application of the Lung Immune Prognostic Index From Research to Clinical Practice

Abstract Full Text
JAMA Oncol. 2020;6(2):299-300. doi:10.1001/jamaoncol.2019.5151

Application of the Lung Immune Prognostic Index From Research to Clinical Practice—Reply

Abstract Full Text
JAMA Oncol. 2020;6(2):300-301. doi:10.1001/jamaoncol.2019.5157

Exercise and Patients With Cancer—Is It Time to Get Heavier With the Dose?

Abstract Full Text
JAMA Oncol. 2020;6(2):301. doi:10.1001/jamaoncol.2019.5404

Late Recurrences After Estrogen Receptor–Positive Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(2):301-302. doi:10.1001/jamaoncol.2019.5579
Correction

Errors in Table

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):302. doi:10.1001/jamaoncol.2019.6210

Errors in Figure 3

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):302. doi:10.1001/jamaoncol.2019.6477

Missing Panels in Figure 1

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):302. doi:10.1001/jamaoncol.2019.6910

Error in Table 2

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):302. doi:10.1001/jamaoncol.2019.6921
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):173. doi:10.1001/jamaoncol.2019.4203
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2020;6(2):171. doi:10.1001/jamaoncol.2019.4202
×